1ZP2MA

1ZP2MA
Clinical data
Other names	[1-(Indolizin-1-yl)propan-2-yl](methyl)amine; 1-(Indolizin-1-yl)-N-methylpropan-2-amine; Compound 26-5; Indolizine-NM-AMT; Indolizine-NM-αMT
Drug class	Monoamine releasing agent
Identifiers
	IUPAC name 1-indolizin-1-yl-N-methylpropan-2-amine;
PubChem CID	168256424;
Chemical and physical data
Formula	C12H16N2
Molar mass	188.274 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=C2C=CC=CN2C=C1)NC;
	InChI InChI=1S/C12H16N2/c1-10(13-2)9-11-6-8-14-7-4-3-5-12(11)14/h3-8,10,13H,9H2,1-2H3; Key:FMOIPWVAARKPNM-UHFFFAOYSA-N;

1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent and an indolizine derivative.^[1] It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring.^[1] 1ZP2MA has been found to be a potent dopamine releasing agent, with an EC₅₀ of 62 nM.^[1] It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)).^[1] 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.^[1]

References

^ ^a ^b ^c ^d ^e WO patent 2023183613A2, Baggott MJ, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen